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dria. A specific conformation of A  42 and human amylin de-
termines toxicity. Finally, trapping of JIP1 by phosphorylated 
tau in the neuronal soma emerges as a fundamental 
pathomechanism in neurodegeneration. 
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 A central question in Alzheimer’s disease (AD) re-
search is how   -amyloid (A  ) and tau, principal compo-
nents of amyloid plaques and neurofibrillary tangles, ex-
ert toxicity. Recent findings highlight the role of distinct 
A  species including A  * 56, a dodecameric form of A  
 [1] . Others demarcate differences between oligomeric 
and fibrillar forms  [2] . For tau, inducible transgenic mice 
reveal a toxicity independent of neurofibrillary tangles 
 [3] , a notion supported by studies in transgenic flies  [4] . 
Irrespective of the form of toxic species, A  and tau seem 
to confer toxicity synergistically, as A  exacerbates a pre-
existing tau pathology  [5] , while A  toxicity is tau depen-
dent  [6] .
 An excellent read-out for functional impairment is 
mitochondrial respiration  [7] . A sophisticated set of func-
tional assays is available determining activities of all mi-
tochondrial complexes separately, as well as different 
forms of respiration. Mitochondrial function is vital for 
any type of cell, in particular neurons; however, mito-
chondria are also the major source of reactive oxygen spe-
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 Abstract 
 Background: How   -amyloid (A  ) and tau exert toxicity in 
Alzheimer’s disease is only partly understood. Major ques-
tions include (1) which aggregation state of A  confers toxic-
ity, (2) do amyloidogenic proteins have similar mechanisms 
of toxicity, and (3) does soluble tau interfere with cellular 
functions?  Methods: To determine A  toxicity in P301L mu-
tant tau transgenic mice, mitochondrial function was as-
sessed after insult with monomeric, oligomeric and fibrillar 
A  . Amylin and A  toxicity were compared in cortical and 
hippocampal long-term cultures. To determine tau toxicity, 
K369I mutant tau mice were established as a model of fron-
totemporal dementia, analyzed biochemically and com-
pared with human diseased brain.  Results: Oligomeric and 
fibrillar A  42 were both toxic, although to different degrees. 
Human amylin shared toxicity with A  42, an effect not ob-
served for nonamyloidogenic rat amylin. Clinical features of 
K369I tau mice were caused by aberrant interaction of phos-
phorylated tau with JIP1, a component of the kinesin trans-
port machinery.  Conclusion: Our data support the notion of 
a synergistic action of tau and A  pathology on mitochon-
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cies. Microtubules are needed to properly distribute mi-
tochondria, establishing a link to tau as microtubule-
stabilizing protein. To determine how mitochondrial 
function is impaired by A  , we isolated mitochondria 
from P301L tau transgenic mice  [5] and incubated them 
with different forms of A   [8] . Both oligomeric and fibril-
lar, but not disaggregated (mainly monomeric) A  42 
caused a decreased mitochondrial membrane potential 
in cortical brain cells obtained from the transgenic mice. 
This was not observed with cerebellar preparations (an 
area where the transgene is not expressed), indicating a 
role for tau in mediating A  42 toxicity. Furthermore, we 
found reductions in state 3 respiration, the respiratory 
control ratio and uncoupled respiration when incubating 
transgenic mitochondria either with oligomeric or fibril-
lar preparations of A  42. Finally, aging of the peptides 
specifically increased the sensitivity of mitochondria to 
oligomeric A  42. We found that oligomeric and fibrillar 
A  42 are both toxic, but to a different degree. Further-
more, we found that aging of the mice increased sensitiv-
ity of mitochondria to A  damage, in agreement with 
studies in A  plaque-forming amyloid precursor protein 
transgenic mice  [9] .
 Epidemiological, clinical and biochemical studies es-
tablish a link between AD and type 2 diabetes, another 
leading cause of morbidity and mortality in the elderly 
 [10] . Both diseases are characterized by amyloidosis in 
their target tissue; amylin aggregation in type 2 diabetes 
is associated with   -cell loss while A  aggregation in AD 
brain is associated with neuronal loss. A  and human 
amylin are similar in size; however, while sharing little 
similarities in their primary sequence, they fold into sim-
ilar secondary structures. Given these similarities, we 
asked whether human amylin would exert neurotoxic ef-
fects similar to A   [11] . Cell type specificity of toxicity 
was explored by comparing cortical to hippocampal long-
term cultures, and aged peptide preparations were com-
pared with nonaged preparations. We found that, dif-
ferent from nonamyloidogenic rat amylin, A  42 and
human amylin both caused a dose-, time- and cell type-
specific neurotoxicity, supporting the notion of a similar 
toxic mechanism  [11] . Depending on the cell type, this 
finding is also supported by coincubation of amylin and 
A  . We observed that in general, hippocampal neurons 
were more sensitive than cortical neurons to toxicity ex-
erted by either human amylin or A  42. We also found 
that rat amylin, which does not form fibrils, is virtually 
not toxic to hippocampal neurons but surprisingly, toxic 
to cortical neurons under some conditions. Coincubation 
of A  42 and human amylin suggests the possibility of a 
shared pathway in hippocampal neurons, whereas more 
than one pathway may be activated in cortical neurons. 
Our results imply that specific conformational changes 
in peptides are important determinants of toxicity. In 
support, conformational antibodies can be generated 
that recognize a generic amyloid fibril epitope found on 
amyloid-like aggregates derived from proteins such as 
transthyretin, amylin or   2 -microglobulin  [12] .
 Not only is the toxicity of A  42 not fully understood, 
the same holds true for tau, where soluble species more so 
than the fibrillar forms seem to be a culprit in disease 
initiation. To determine tau toxicity, we generated a nov-
el transgenic mouse strain, K3, which expresses human 
tau carrying the mutation K369I found in a familial case 
of frontotemporal dementia (FTD). The mice develop a 
progressive histopathology reminiscent of the human pa-
tient. Furthermore, they show early onset memory im-
pairment and amyotrophy, that precedes neurodegenera-
tion as the mice age. Different from our previously gener-
ated tau transgenic strains, K3 mice express the transgene 
in the substantia nigra, associated with an early onset 
motor phenotype that reproduces parkinsonism with 
tremor, bradykinesia, abnormal gait and postural insta-
bility. Interestingly, motor performance of young, but not 
old K3 mice could be improved upon  L -dopa treatment, 
which bears similarities to parkinsonism in FTD. The 
early onset symptoms in the mice are mechanistically re-
lated to selectively impaired anterograde transport of dis-
tinct cargos, which precedes loss of dopaminergic neu-
rons in aged mice. The impaired axonal transport affects, 
among others, vesicles containing the dopamine-synthe-
sizing enzyme tyrosine hydroxylase. Distinct modes of 
transport are also impaired in sciatic nerve, which may 
explain amyotrophy  [13] . We found that impaired axonal 
transport in the K3 mice is due to a cargo-selective im-
pairment of kinesin-driven anterograde transport by tau. 
Specifically, formation of the kinesin motor complex for-
mation is disturbed in K3 mice, as hyperphosphorylated 
tau interacts with JIP1, a protein associated with the ki-
nesin motor protein complex. Consequently, JIP1 trans-
port into the axon is impaired causing accumulation in 
the soma. Since we found trapping of JIP1 in the soma 
and a pathological tau/JIP1 interaction also in AD brain, 
this has pathomechanistic implications for tauopathies. 
We also found JIP1 sequestration in the soma of tau-
transfected primary neuronal cultures. The pathological 
tau/JIP1 interaction depends on tau phosphorylation, 
with tau competing with the physiological binding of 
JIP1 to kinesin light chain. Since JIP1 is involved in regu-
lating cargo binding to kinesin motors, our findings may, 
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at least in part, explain how hyperphosphorylated tau, 
independent of effects mediated by amyloid precursor 
protein/A  42, mediates impaired axonal transport in 
both AD and FTD  [14] .
 Together, this highlights the validity of transgenic an-
imal models  [15] and underscores the role of impaired ax-
onal transport in human neurodegenerative disease  [16] .
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